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GTPases and kinases are two predominant signaling modules that regulate cell fate.
Dysregulation of Ras, a GTPase, and the three eponymous kinases that form key nodes of
the associated phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway
have been implicated in many cancers, including pancreatic cancer, a disease noted for its
current lack of effective therapeutics. The K-Ras isoform of Ras is mutated in over 90% of
pancreatic ductal adenocarcinomas (PDAC) and there is growing evidence linking aberrant
PI3K/AKT/mTOR pathway activity to PDAC. Although these observations suggest that
targeting one of these nodes might lead to more effective treatment options for patients
with pancreatic and other cancers, the complex regulatory mechanisms and the number of
sequence-conserved isoforms of these proteins have been viewed as significant barriers
in drug development. Emerging insights into the allosteric regulatory mechanisms of these
proteins suggest novel opportunities for development of selective allosteric inhibitors
with fragment-based drug discovery (FBDD) helping make significant inroads. The fact
that allosteric inhibitors of Ras and AKT are currently in pre-clinical development lends
support to this approach. In this article, we will focus on the recent advances and merits
of developing allosteric drugs targeting these two inter-related signaling pathways.
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INTRODUCTION
Dysregulation of cellular signaling pathways that involve phos-
phoryl transfer through GTPase and kinase activities is a key step
in the initiation and development of neoplasms (Hanahan and
Weinberg, 2011). Among the GTPases, constitutive Ras activa-
tion plays a critical role in the development of pancreatic, colon,
and lung cancers, and is an indicator of poor prognosis (Kim
et al., 2006; Califano et al., 2012; Pérez-Ruiz et al., 2012), with
the Kristin isoform of Ras (K-Ras) being mutated in over 90% of
pancreatic ductal adenocarcinomas (PDAC) (Morris et al., 2010).
Until recently, development of therapeutically relevant K-Ras
inhibitors had been unsuccessful due in large part to the pro-
tein’s picomolar affinity for GDP and GTP (John et al., 1990).
However, structural studies, including computational chemistry
techniques (Grant et al., 2011) and fragment-based drug discov-
ery (FBDD) (Maurer et al., 2012; Sun et al., 2012; Ostrem et al.,
2013), have begun to explore novel allosteric-based opportunities
for drugging this notoriously recalcitrant enzyme.
Phosphatidylinositol 4,5-bisphosphate 3-kinases (PI3K) form
a key node in the PI3K/AKT/mTOR pathway, regulating numer-
ous biological processes through phosphoryl transfer (Katso et al.,
2001). Through its association with Ras, this family of kinases
has been implicated as key driver in pancreatic cancer (Eser et al.,
2013). Selectivity has been a major stumbling block in drugging
PI3K since a large number of sequence-conserved isoforms play
distinct yet overlapping functions within the cell (Vanhaesebroeck
et al., 2010). However, as with Ras, computational chemistry
techniques and FBDD have helped develop some promising new
avenues in selectively targeting various isoforms (Giordanetto
et al., 2011, 2012; Hughes et al., 2011), albeit through competitive
inhibitors that bind the active site. Selective PI3K inhibition by
allosteric means may soon emerge from recent reports that have
begun to decipher the activation mechanism of these enzymes
(Burke et al., 2012; Hon et al., 2012). Two other major nodes of
the PI3K/AKT/mTOR pathway, AKT andmTOR, form additional
focal points for the development of novel therapeutics. As with
Ras and PI3K, these two enzymes have benefited from structural
studies aimed at gaining greater understanding of their mecha-
nisms of action and, as a consequence, have provided opportunity
for novel allosteric-based approaches to their inhibition.
In the context of Ras and the PI3K/AKT/mTOR pathway,
this mini-review discusses recent advances in the development
of selective inhibitors with a focus on novel druggable allosteric
sites, as well as highlighting some unexpected and undesirable
outcomes associated with compounds that target catalytic sites.
Some of the most salient areas of research are presented below
and is intended to give the reader an overview of an exciting new
arena of drug discovery.
INHIBITORS OF Ras
Ras proteins form key nodes in a wide array of signaling path-
ways (Malumbres and Pellicer, 1998) and as a consequence
aberrant Ras function can result in cancer. There are over 30
Ras-subfamily members (Wennerberg et al., 2005); due to their
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sequence similarity, number and diverse function, development
of selective compounds is critical in minimizing the likelihood
of drug toxicity. As shown below, the past few years have seen
remarkable progress toward reaching this goal due in large part
to the application of FBDD.
Structural studies have shown that Ras undergoes a large
conformational change upon turnover, driven by hydrolysis of
the γ-phosphate of GTP as seen from comparison of the GDP
product-bound co-structure to a non-hydrolysable GTP analog
(GMPPNP) co-structure (Milburn et al., 1990). In the GTP-
bound “on” state, two sections of the active site, switch I and
switch II, pack around the terminal phosphate. In the GDP-
bound “off” state, with the γ-phosphate moiety removed, the
catalytic site opens up, altering the surface topology. This impairs
Ras’ ability to activate a variety of effector proteins, including
PI3K (Rodriguez-Viciana et al., 1994; Castellano and Downward,
2010). Mutations in switch I, switch II, or the p-loop (a region
that recognizes the β-phosphate of the nucleotide) promote the
oncogenic properties of Ras (Pai et al., 1989; Milburn et al.,
1990; Prive et al., 1992; Scheffzek et al., 1997). Additionally, two
classes of ancillary proteins directly interact and promote Ras’
adoption of either the “on” or “off” state; GTPase-activating pro-
teins (GAPs) enhance Ras’ intrinsically slow GTPase activity to
drive formation of the “off” conformer, and guanine nucleotide
exchange factors (GEFs) promote exchange of GDP for GTP to
switch the enzyme back to its “on” state.
Mutations in all four clinically relevant isoforms of Ras
(H-Ras, N-Ras, and splice variants K-Ras-4A and K-Ras-4B)
are known to cause a variety of cancers, with K-Ras being the
most frequently mutated isoform in pancreatic cancer (COSMIC
database, Sanger Institute). As mutations in Ras are common to a
variety of cancersmany different strategies that aim to down regu-
late constitutively active mutant forms have been explored (Gysin
et al., 2011); however, until recently, lack of progress resulted
in this family of proteins being largely regarded as undruggable
(Sawyers, 2009). Development of competitive inhibitors that sta-
bilize a GDP-bound inactive conformation must overcome Ras’
picomolar affinity for GTP (John et al., 1990), inherently low
GTPase activity (John et al., 1993), and high intracellular con-
centrations of GTP (Traut, 1994). Furthermore, the lack of any
obvious druggable sites on the enzyme surface beyond the active
site (Ahmadian et al., 1999) suggests inhibition is unlikely to be
achieved by an allosteric approach. To circumvent these perceived
barriers, compounds that inhibit farnesyl transferase, the enzyme
that prenylates Ras at the C-terminus (Kohl et al., 1994; Lingham
et al., 1998), were developed in an attempt to prevent Ras from co-
localizing with effector proteins on the inner-face of the plasma
membrane. Unfortunately, cells have been shown to maintain Ras
prenylation, and therefore recruitment to themembrane, through
gerenylgerenylation of the cysteine moiety (Whyte et al., 1997).
New approaches to compound screening have begun to change
the mindset of Ras being a poor drug target. Glycine 12 of K-Ras,
which forms part of the p-loop, is a common locus for amino
acid substitution in many cancers, with G12C being the fourth
most frequently substituted amino acid in oncogenic K-Ras for
both PDAC and cancers in general (COSMIC database, Sanger
Institute). This observation prompted Ostrem and co-workers
to use mass spectrometry to screen a library of fragment-like
compounds that contain reactive sulfur moieties for ones which
covalently modified K-RasG12C (an approach known as tethering)
(Ostrem et al., 2013). Compounds were identified and, through
medicinal chemistry efforts, lead compounds were developed
that selectively modified mutant K-Ras by binding to a novel
allosteric pocket, termed S-IIP, that is formed in part by the switch
II motif (Figure 1A and Table 1B). Structural analyses of cova-
lently modified protein demonstrated that Ras can be stabilized
in a GDP-bound inactive conformation. Interestingly, two other
groups have isolated compounds using FBDD that both bind
K-Ras in a hydrophobic pocket adjacent to the switch I/II motifs
(Figure 1A and Table 1B), blocking SOS-mediated nucleotide
exchange (Maurer et al., 2012; Sun et al., 2012). Whether or not
this new insight will aid in the development of non-covalent
allosteric therapeutics that specifically target the more common
G12V and G12D K-Ras amino acid substitutions that are associ-
ated with cancers of the pancreas and large intestine remains to
be seen.
INHIBITORS OF PI3K/AKT/mTOR PATHWAY
The PI3K/AKT/mTOR pathway forms one of many mechanisms
that regulate progression though the cell cycle and cellular apop-
tosis (Chang et al., 2003). Unsurprisingly, dysregulation of a
component in this pathway can give rise to cancer. The three
major nodes of the PI3K/AKT/mTOR pathway are: PI3K, a fam-
ily of related kinases that primarily phosphorylate lipid-based
phosphatidylinositol secondary messengers upon activation by
receptors on the cell surface, AKT (Rac/protein kinase B), a kinase
that binds the PIP (phosphatidylinositol phosphate) products
of PI3K via its pleckstrin homology (PH) domain for recruit-
ment to the plasma membrane, and mTOR (mammalian target
of rapamycin). Due to the large and diverse array of down-stream
effectors, each one of these three enzymes forms a node that has
significant appeal in the development of therapeutics that tar-
get pancreatic and other cancers. Below we describe some of the
efforts made toward this goal with an emphasis on the advantages
gained by development of allosteric compounds.
PI3K
The PI3K family is comprised of four classes of kinases that can
be further divided based on their subunit assembly; they are com-
posed of one of eight distinct catalytic subunits and, depending
on the class, a regulatory subunit (Vanhaesebroeck et al., 2010)
with p110α and p85α, being the most well characterized cat-
alytic and regulatory subunits, respectively. The combination of
catalytic and regulatory subunits defines individual PI3K func-
tion, with mutations in the corresponding genes associated with
specific cancers (Liu et al., 2009).
Functional diversity necessitates the development of selective
PI3K inhibitors. In contrast to other targets mentioned in this
review, advances in PI3K selectivity have been brought about by
the discovery and development of compounds that target the
active site. Knight and colleagues made early insights into the
development of selective non-allosteric inhibitors using in vitro
assays to screen a panel of diverse PI3K inhibitors against PI3K
family members (Knight et al., 2006). Three crystal structures
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FIGURE 1 | Structures of human K-Ras, AKT1 and mTOR complexed
with allosteric inhibitors. For compound structures refer to Table 1,
N- and C-terminal are highlighted. (A) The overall structure of K-Ras
shown in ribbon representation (PDB ID: 3GFT) with switch I, switch II,
and the p-loop highlighted. The active site is marked by nucleotide
analog substrate, GMPPNP, and is illustrated in red. Allosteric inhibitors
are shown with the following color scheme; 4,6-dichloro-2-methyl-3-
aminoethyl-indole (PDB ID: 4DST), pink; compound 13 (PDB ID: 4EPY),
gold; compound six (PDB ID: 4LUC), green; compound eight (PDB ID:
4LYF), gray. The latter two compounds are covalently attached to the
side-chain of Cys13, highlighted by the Cβ and Sγ-atoms colored blue
and yellow, respectively. (B) The overall fold of the PH and kinase
domains of AKT1 shown in ribbon representation (PDB ID: 3O96), with
the N-terminal PH colored pink and the C-terminal kinase domain in
coral. The active site is marked out by AMPPNP (from PDB ID: 4EKK)
and illustrated in red, inhibitor VIII is shown as pale yellow. (C) Crystal
structure of mTORN, shown as blue ribbons, complexed with
regulatory protein mLST8, shown as green ribbons (PDB ID: 4JSP).
FKBP12 (PDB ID: 1FAP) (yellow) which recruits allosteric inhibitor
rapamycin (shown in magenta) is superimposed onto the complex using
mTOR’s FRB domain (highlighted in slate blue) as a reference.
Substrate analog ATPγS is shown in red.
of compounds bound to catalytic subunit p110γ were solved,
including a p110δ-selective non-allosteric inhibitor that is a close
analog of Idelalisib [previously known as GS-1101/CAL-101 (May
et al., 2008)], a drug that has recently been approved by the FDA
for the treatment of a number of blood-related cancers. From
these structures, two regions lining the active site, an inducible
hydrophobic “selectivity” pocket and an “affinity” pocket, were
identified that are thought to contribute to the binding prop-
erties of a given ligand. It appears serendipity of target choice
and the unique plasticity of the PIK3 active site rather than
design have played the key roles in the development of selective
PI3K competitive inhibitors as efforts to find further isoform-
selective inhibitors using fragment-based screening methods have
also produced compounds that target the active site (Giordanetto
et al., 2011, 2012; Hughes et al., 2011).
Recent biophysical and structural data have begun to shed light
on the allosteric mechanism of PI3K regulation. Burke and col-
leagues used results from mass spectrometry experiments with
PI3K isoform p110α/p85α to propose an activation and recruit-
ment model which occurs in four distinct steps in an as-of-yet
unknown order (Burke et al., 2012): disruption of two distinct
p110α/p85α interfaces (which are promoted by phosphorylated
receptor tyrosine kinase andmembrane binding), conformational
change within the catalytic p110α subunit (possibly to allow cor-
rect orientation on the membrane surface), and lipid substrate
binding at the active site. To further highlight the complexity
of PI3K regulation, a recent report has shown through SPR and
kinase activity assays that p110α substrate binding and kinase
activity is modulated by membrane composition (Hon et al.,
2012). Interestingly, this same group reported crystallographic
evidence of a novel inducible ligand-binding site distinct from
the active site of p110α, but were unable to demonstrate whether
or not this could be exploited to inhibit kinase activity. Given
that not all PI3K isoforms include a regulatory subunit, and that
the activation mechanism of class I kinases is likely dependent
on subunit composition (Burke et al., 2011; Zhang et al., 2011),
additional selective PI3K inhibition though allostery might be
achieved by taking advantage of multiple druggable sites rather
than one site shared between all isoforms.
AKT
AKT is an effector kinase downstream from PI3K forming
another node of potential therapeutic value. There are three iso-
forms of AKT (AKT1-3) all containing an N-terminal PH domain
that binds PIP3, a central AGC kinase domain, and a hydrophobic
C-terminal domain. After recruitment to the plasma membrane
through binding PIP3, AKT is activated by two phosphorylation
events: one on its activation loop (Thr308, AKT1 numbering)
by membrane-associated PDK1 and the other on the C-terminal
hydrophobic motif by mTORC2 (Ser473) (Sarbassov et al., 2005).
Mounting evidence suggests each isoform performs a specific
function (Santi and Lee, 2010); however, most current knowledge
on the importance of selectively targeting each isoform derives
from their differing roles in the initiation and progression of
cancers (Agarwal et al., 2013).
The PH and AGC kinase domains present attractive drug tar-
gets within AKT; small molecule binding to the AGC kinase
domain would directly inhibit upregulated kinase activity, while
binding to the PH domain would prevent recruitment to the
plasmamembrane and therefore hinder activation by PDK1. Both
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Table 1 | (A) Allosteric inhibitors currently either FDA approved or in clinical trials that target major nodes of the PI3K/AKT/mTOR pathway. (B)
A selection of compounds reported as allosteric inhibitors of Ras and major nodes of the PI3K/AKT/mTOR pathway.
(A)
Compound Target Cancer Stage of development Structure
MK-2206 AKT1/2 Pancreatic/colon/breast/lung Phase I/II
Everolimus mTOR Renal cell carcinoma Approved
Temsirolimus mTOR Renal cell carcinoma Approved
(B)
Compound Target References Structure
Compound 6 K-Ras (G12C) Ostrem et al., 2013
Compound 8 K-Ras (G12C) Ostrem et al., 2013
4,6-dichloro-2-methyl-3-aminoethyl-indole K-Ras/ H-Ras Maurer et al., 2012
Compound 13 K-Ras Sun et al., 2012
Inhibitor VIII AKT1/2 Lindsley et al., 2005
domains are highly conserved between the three isoforms [kinase
domains are ∼85% identical and the PH domains are ∼60%
identical (Barnett et al., 2005a)] as well as being conserved in
a diverse array of functionally unrelated proteins, thus requir-
ing development of compounds that exhibit a high degree of
selectivity. There are four types of AKT inhibitors currently in
development: ATP-competitive inhibitors, analogs of PIP3, sub-
strate peptidomimetics, and allosteric modulators (Kumar and
Madison, 2005; Collins, 2009). ATP-competitive inhibitors are the
most mature in terms of development, with the first series of AKT
selective compounds reported in 2002 based on a PKA inhibitor
(Reuveni et al., 2002); however, significant obstacles remain due
to the isoforms possessing near identical nucleotide-binding sites
(Kumar and Madison, 2005) and that competitive inhibitors have
been found to unexpectedly hyperphosphorylate AKT through an
intrinsic regulatory mechanism (Okuzumi et al., 2009).
A decade ago Merck reported on the discovery of compounds
that only inhibit AKT kinase activity in the presence of the PH
domain (Barnett et al., 2005b). Enzyme kinetics on full length and
PH domain deleted AKT constructs showed these compounds to
be allosteric inhibitors. Subsequent work by the team resulted
in the development of MK-2206 (Table 1A), a drug that shows
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moderate selectivity for AKT1/2 over AKT3 (Yan, 2009), and
is currently in clinical trials for a wide variety of cancers. The
structure of another isoform-selective allosteric inhibitor pro-
duced by this research program, inhibitor VIII [(Lindsley et al.,
2005) and Table 1B], has been solved in complex with an AKT1
construct containing both PH and kinase domains, giving struc-
tural evidence of an allosteric regulatory mechanism in which
changes in relative positioning of the two domains regulates activ-
ity (Wu et al., 2010). The inhibitor was shown to bind AKT1
between the PH and kinase domains (Figure 1B) to lock the
protein in a “PH-in” conformation, preventing ATP access to
the nucleotide-binding site. Furthermore, the authors inferred
that active site competitive inhibitors hyperphosphorylate AKT
as a consequence of only binding to a “PH-out” conformation,
preventing the PH domain from fully closing onto the kinase
domain. This would result in keeping the phospholipid-binding
site exposed and enhancing AKT’s recruitment to the membrane
where it becomes phosphorylated. These observations suggest
how allosteric approaches to drugging a target might offer signif-
icant advantages over more conventional approaches to enzyme
inhibition.
mTOR
Mammalian target of rapamycin (mTOR) is a member of the
serine/threonine phosphatidyl inositol 3′ kinase-related kinase
family (PIKK) that uniquely phosphorylates protein substrates
and is sensitive to rapamycin, a large macrocyclic compound that
is synthesized by Streptomyces hygroscopicus as an antifungal agent
(Vezina et al., 1975). Rapamycin does not directly bind mTOR
alone, but forms a complex with cyclophilin FKB12. This protein-
inhibitor complex inhibits kinase activity by binding to mTOR’s
FKBP12-rapamycin binding (FRB) domain and restricting access
to the active site (Huang et al., 2003; Yang et al., 2013). mTOR
is part of two multi-protein complexes, mTORC1, composed
of mTOR, mLST8, DEPTOR, RAPTOR, and AKT1S1/PRAS40,
and mTORC2, composed of mTOR, mLST8, DEPTOR, PRR5,
RICTOR, and MAPKAP1. mTORC2 is regarded as lacking sensi-
tivity to rapamycin due to RICTOR preventing mTOR-FKBP12-
rapamycin complex formation (Sarbassov et al., 2004); however,
prolonged exposure appears to overcome this through inhibition
of free mTOR prior to its assembly into the mTORC2 complex
(Sarbassov et al., 2006). Both complexes regulate cell growth,
but perform distinct roles within the cell; mTORC1 promotes
mRNA translation, ribosome biogenesis, and autophagy, while
mTORC2 promotes entry into the cell cycle, cell survival, remod-
eling of the cytoskeleton, and metabolism (Sabatini, 2006). As
part of mTORC1, mTOR serves as a downstream effector of AKT,
where activated AKT indirectly activates mTORC1 (Inoki et al.,
2003). In contrast, mTORC2 phosphorylates AKT at Ser473 to
upregulate pathway activity (Sarbassov et al., 2005). Surprisingly,
rapamycin-based inhibition of mTORC2 has been shown to para-
doxically increase levels of AKT phosphorylation; however, in
contrast to the intrinsic mechanism of AKT hyperphosphoryla-
tion by AKT competitive inhibitors, this has been shown to occur
through an extrinsic negative feedback mechanism that results in
Ser473 hyperphosphorylation by PI3K (O’Reilly et al., 2006). This
observation suggests that a combinatorial therapy that attenuates
feedback loops, such as addition of a PI3K inhibitor, might be an
effective way to increase drug efficacy.
Being a member of the PIKK family, it is unsurprising that
many compounds developed to target the ATP-binding site of
PI3K can also inhibit mTOR (Garcia-Echeverria and Sellers,
2008). In contrast, rapalogs (analogs of rapamycin) are selective
allosteric inhibitors of mTOR, with Temsirolimus and Everolimus
being approved by FDA for the treatment of renal cell carcinomas.
The recent crystal structure of a truncated mTOR that includes
the FAT (focal adhesion targeting), FRB (FKBP12-rapamycin-
binding) and kinase domains sheds some light on the mechanism
of its regulation (Yang et al., 2013); using the FRB domain as
a point of reference, the FKBP12 subunit can be superimposed
onto the complex and suggests the FKBP12-rapamycin complex
inhibits mTOR activity by occluding access to the active site
(illustrated in Figure 1C). The authors mapped hyperactivating
mutational hotspots onto the structure to show clustering at three
sites and rationalized that the majority of these mutations have
a destabilizing effect, particularly on an inhibitory α-helix that
results in improved access to the active site. Such effects on pro-
tein structure could present opportunities in the development of
allosteric compounds that stabilize an inactive state, as that shown
for K-Ras.
To the best of the authors’ knowledge, there are no
publications applying methods such as FBDD to develop
non-rapamycin-based compounds that target selective
allosteric sites remote from the active site or to interfere
with mTORC1/mTORC2 assembly. Additionally, all known
mTOR selective drugs currently in clinical trials cannot distin-
guish between mTORC1 and mTORC2. Given the size of the
protein (290 kDa) and the complex nature of its multi-protein
assembly, there is likely significant opportunity to develop
selective drugs that modulate mTORC1/mTORC2 activities and
hence deliver more fine-tuned treatments for cancer.
FUTURE DEVELOPMENTS
Allosteric compounds are making it into mainstream drug devel-
opment due in part to recent advances in structural biology and
biophysical techniques, FBDD, and computational chemistry. As
summarized in this mini-review, recent drug discovery programs
have shown that allosteric inhibitors may have an edge over more
common active site-competitive inhibitors, particularly when tar-
geting specific members of a family of related proteins. An added
benefit to this approach appears to be the reduction in likeli-
hood of obtaining unexpected and undesired results like that
seen in hyperphosphorylated AKT. The emerging knowledge of
allosteric regulatory mechanisms of therapeutically important
targets, such as PI3K, may aid in future allosteric drug develop-
ment, although caution should be noted, as some targets are likely
to remain intractable to allosteric inhibition by their intrinsic
nature.
Unlike the discovery and development of drugs that target
active sites, allosteric drug discovery may present more of a chal-
lenge as methodologies for detection and analysis of hit and lead
compounds are still maturing. However, emerging technologies,
such as micro-scale thermophoresis for compound screening and
diversity oriented synthesis for library design, may help accelerate
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the discovery and development of drugs that allow effective
treatment of currently incurable cancers such as PDAC.
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